BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile


Shire Pharmaceuticals 

725 Chesterbrook Boulevard

Wayne  Pennsylvania  19087-5637  U.S.A.
Phone: 484-595-8800 Fax: 484-595-8900


There’s a simple purpose that sits at the heart of our business: to enable people with life-altering conditions to lead better lives. This means we focus on developing treatments for conditions where the impact of our medicines can make an immediate and tangible difference for patients.

Our growth strategy is to focus on developing and marketing innovative specialty medicines for symptomatic conditions to meet significant unmet patient needs. Our two strategic priorities are to drive optimum performance of our existing products, enabling access to these medicines for patients today; and building our pipeline through research and development (R&D) and business development (BD), delivering access in the future for patients

We are always looking for talented people to join the Shire team. To learn more about Shire, visit For more information on career opportunities with Shire, please visit: .

Shire. To be as brave as the people we help.

 Key Statistics

Ownership: Public

Web Site: Shire Pharmaceuticals
Employees: 336
Symbol: SHPG


 Company News
Shire’s Investigational SHP609, Idursulfase-IT, Receives FDA Fast Track Designation For The Treatment Of Neurocognitive Decline Associated With Hunter Syndrome 1/26/2015 9:12:45 AM
Shire R&D Day Profiles Innovative Pipeline Expected To Contribute $3 Billion In Product Sales By 2020 12/10/2014 9:06:29 AM
Shire Release: Phase 3 Guanfacine Hydrochloride Extended Release (GXR) Study Shows Improvement In Core Symptoms Of Attention-Deficit/Hyperactivity Disorder (ADHD) In Children And Adolescents 12/8/2014 2:06:24 PM
Here’s What An AbbVie (ABBV)-Shire Split Might Mean For Massachusetts 10/17/2014 6:40:14 AM
The Reason Why Shire Is Moving Its HQ From Ireland To The U.K. 10/10/2014 6:37:10 AM
AbbVie (ABBV) Sued By Louisiana Pension Fund Over $54.5 Billion Shire Pharmaceuticals (SHPG) Deal 9/18/2014 6:38:01 AM
Shire Announces Award Recipients For 2014 Michael Yasick ADHD Scholarship 7/29/2014 10:30:13 AM
Shire Delivers Record Quarterly Revenues And Non GAAP Diluted Earnings Per ADS Up 42%. 7/18/2014 8:14:55 AM
Federal Trade Commission Urged To Probe Shire, Sanofi (France) (SAN.PA) & Icahn Med School Over A "Conspiracy" 7/16/2014 6:44:55 AM
Shire Pharmaceuticals (SHPG) Release: Vyvanse® Patents Found To Be Infringed And Valid By U.S. District Court 6/25/2014 6:32:20 AM